Blood (2018) 132 (Supplement 1): 5856. https://doi.org/10.1182/blood-2018-99-113198

Authors:

Camila Peña, MD, Gonzalo P Mendez, MD, Natalia Paola Schutz, MD, Eloisa Riva, MD, Ricardo Valjalo, MD, Hernán López-Vidal, MD, Alejandro Majlis, MD, Vivianne Lois, MD, Daniela Zamora, MD, Jose T Gonzalez, MD, Dorotea Beatriz Fantl, MD

Abstract:

Monoclonal gammopathy of renal significance (MGRS) is a recently defined entity. It is a group of renal diseases due to paraprotein deposition from a small B lymphocyte or plasma cell clon, not meeting the criteria for an overt gammopathy-associated neoplasm. Despite this feature, the secondary kidney damage may be severe and irreversible; therefore, its early recognition and treatment are crucial. There are few studies on MGRS in the international literature, and no reported data from Latin America (LA).